Abstract
Therapeutic benefits of alpha1-adrenergic antagonists (A1As), namely, prazosin, terazosin and doxazosin, have begun to emerge in a broad range of psychiatric disorders in clinical trials. A1As have shown promise in the treatment of several psychiatric disorders such as posttraumatic stress disorder (PTSD), alcohol dependence, cocaine dependence, nicotine cessation and dementia-related agitation in both animal and human studies. These, and other chronic psychiatric conditions, may be mediated or precipitated by stressful conditions. A1As beneficial effects in these psychiatric disorders are hypothesized via their unique effects on regulating norepinephrine (NE) and corticotrophin releasing factor (CRF), which are two key mediators of stress in the central nervous system (CNS). Despite increasing use of A1As in psychiatric disorders, there is a lack of comprehensive review. Animal studies have suggested that by regulating NE in stressful conditions, A1As can increase the pre-frontal cortical functioning and decrease amygdalar activity. Similarly, rat studies have shown a direct decrease in cerebrospinal fluid (CSF) expression of CRF in rats treated with prazosin in stressful conditions. Thus, A1As may have potential benefit in the treatment and secondary prevention of stress-mediated or precipitated psychiatric disorders. In addition, another beneficial effect of A1As is known to be on improvement of metabolic parameters such as lipid profile and insulin sensitivity.
Keywords: Alpha1-adrenergic receptor antagonists, doxazosin, prazosin terazosin, PTSD, secondary prevention in psychiatric disorders, stress, substance use disorders.
Current Psychopharmacology
Title:Alpha1-Adrenergic Receptor Antagonists Use in Treatment and Prevention of Psychiatric Disorders: A Review
Volume: 3
Author(s): Abhishek Wadhawan, Alok Banga, Yinghui Duan, Michel Mennesson and Zhao Helen Wu
Affiliation:
Keywords: Alpha1-adrenergic receptor antagonists, doxazosin, prazosin terazosin, PTSD, secondary prevention in psychiatric disorders, stress, substance use disorders.
Abstract: Therapeutic benefits of alpha1-adrenergic antagonists (A1As), namely, prazosin, terazosin and doxazosin, have begun to emerge in a broad range of psychiatric disorders in clinical trials. A1As have shown promise in the treatment of several psychiatric disorders such as posttraumatic stress disorder (PTSD), alcohol dependence, cocaine dependence, nicotine cessation and dementia-related agitation in both animal and human studies. These, and other chronic psychiatric conditions, may be mediated or precipitated by stressful conditions. A1As beneficial effects in these psychiatric disorders are hypothesized via their unique effects on regulating norepinephrine (NE) and corticotrophin releasing factor (CRF), which are two key mediators of stress in the central nervous system (CNS). Despite increasing use of A1As in psychiatric disorders, there is a lack of comprehensive review. Animal studies have suggested that by regulating NE in stressful conditions, A1As can increase the pre-frontal cortical functioning and decrease amygdalar activity. Similarly, rat studies have shown a direct decrease in cerebrospinal fluid (CSF) expression of CRF in rats treated with prazosin in stressful conditions. Thus, A1As may have potential benefit in the treatment and secondary prevention of stress-mediated or precipitated psychiatric disorders. In addition, another beneficial effect of A1As is known to be on improvement of metabolic parameters such as lipid profile and insulin sensitivity.
Export Options
About this article
Cite this article as:
Wadhawan Abhishek, Banga Alok, Duan Yinghui, Mennesson Michel and Helen Wu Zhao, Alpha1-Adrenergic Receptor Antagonists Use in Treatment and Prevention of Psychiatric Disorders: A Review, Current Psychopharmacology 2014; 3 (3) . https://dx.doi.org/10.2174/2211556004666150507220211
DOI https://dx.doi.org/10.2174/2211556004666150507220211 |
Print ISSN 2211-5560 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-5579 |
Call for Papers in Thematic Issues
Breakthroughs in drug design, development and delivery system for the management of neuro-psychiatric disorders
Neuropsychiatric diseases are one of the main causes of disability, affecting millions of people. Various drugs are used for its treatment, although no effective therapy has been found yet. The blood brain barrier (BBB) significantly complicates drugs delivery to the target cells in the brain tissues. This proposal describes the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Therapeutic Potential of N-Acetylcysteine for Wound Healing, Acute Bronchiolitis, and Congenital Heart Defects
Current Drug Metabolism TAU Aggregation is a Therapeutic Target for Alzheimers Disease
Current Alzheimer Research Reviewing the Cardiovascular Complications of HIV Infection After the Introduction of Highly Active Antiretroviral Therapy
Current Drug Targets - Cardiovascular & Hematological Disorders Review on Patents for Ubiquitin-Proteasome Inhibitor as Medical Advance in Major Human Diseases
Recent Patents on Biomedical Engineering (Discontinued) Oral Glucose-lowering Drugs and Cardiovascular Outcomes: From the Negative RECORD and ACCORD to Neutral TECOS and Promising EMPA-REG
Current Vascular Pharmacology Protein Interaction Studies for Understanding the Tremor Pathway in Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Exploring the Multifunctional Neuroprotective Promise of Rasagiline Derivatives for Multi-Dysfunctional Alzheimer’s Disease
Current Pharmaceutical Design Coumarins as Promising Scaffold for the Treatment of Age-related Diseases – An Overview of the Last Five Years
Current Topics in Medicinal Chemistry Telomere/Telomerase System: A New Target of Statins Pleiotropic Effect?
Current Vascular Pharmacology Novel Anticoagulants vs Warfarin for Stroke Prevention in Atrial Fibrillation
Cardiovascular & Hematological Disorders-Drug Targets Statin Therapy-Evidence Beyond Lipid Lowering Contributing to Plaque Stability
Current Medicinal Chemistry Multiple Roles for Glycogen Synthase Kinase-3 as a Drug Target in Alzheimers Disease
Current Drug Targets Editorial [Hot Topic:Sleep Medicine (Guest Editor: Salim Surani)]
Current Respiratory Medicine Reviews Impacts of Hyper-Homocysteinemia and White Matter Hyper-Intensity in Alzheimers Disease Patients with Normal Creatinine: An MRI-Based Study with Longitudinal Follow-up
Current Alzheimer Research Cognitive Impairment in Depression
Current Psychiatry Reviews Role of the Blood-Brain Barrier in the Pathogenesis of Alzheimers Disease
Current Alzheimer Research Long non-coding RNAs in Alzheimer’s disease
Current Topics in Medicinal Chemistry Pharmacology of the Human Saphenous Vein
Current Vascular Pharmacology The APOE Genotype: Modification of Therapeutic Responses in Alzheimer's Disease
Current Pharmaceutical Design Meta-Analysis of the Effectiveness and Safety of Prophylactic Use of Nimodipine in Patients with an Aneurysmal Subarachnoid Haemorrhage
CNS & Neurological Disorders - Drug Targets